Cargando…
Dosimetry Prediction for Clinical Translation of (64)Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression
The immune checkpoint programmed death 1 receptor (PD-1) expressed on some tumor-infiltrating lymphocytes, and its ligand (PD-L1) expressed on tumor cells, enable cancers to evade the immune system. Blocking PD-1 with the monoclonal antibody pembrolizumab is a promising immunotherapy strategy. Thus,...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766550/ https://www.ncbi.nlm.nih.gov/pubmed/29330552 http://dx.doi.org/10.1038/s41598-017-19123-x |